Compare Genuine Parts Company (GPC) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Genuine Parts Company vs McKesson Corporation — how do they compare? Genuine Parts Company trades at $126.93 (market cap $17.67B), while McKesson Corporation trades at $936.01 (market cap $108.46B). The key difference: McKesson Corporation is far larger — about 6.1× Genuine Parts Company's market cap, and Genuine Parts Company pays the higher dividend (3.32%). Which is the better fit depends on your goals — on Pluang, investors hold Genuine Parts Company for 75 Days and McKesson Corporation for 74 Days on average.
| GPC | MCK | |
|---|---|---|
Market Cap | $17.67B | $108.46B |
Volume | 1,079,458 | 712,607 |
Sector | Consumer Cyclical | Health |
52-Week High | $149.26 | $995.69 |
52-Week Low | $92.47 | $725.17 |
Typical Hold Time | 75 Days | 74 Days |
Enterprise Value | $23.76B | $115.00B |
Dividend Yield | 3.32% | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GPC trades at $125.41, down 1.55% on the day, with a bearish technical signal and mixed fundamentals. The company reported Q2 2026 EPS of $2.15, beating expectations, but net income margin remains thin at 0.13%. Analyst consensus is mixed with 43% buy ratings and a $145.75 price target. The planned Q1 2027 separation of automotive and industrial businesses represents a key catalyst, though profitability concerns persist amid declining cash flow trends.
The outlook remains cautious with near-term pressure from weak technicals and margin compression, balanced by potential upside from the corporate split. Key risks include execution of the separation, competitive pressures in auto parts distribution, and macroeconomic sensitivity. The stock offers value at current levels for investors betting on successful restructuring, but requires careful monitoring of Q3 earnings due October 20, 2026.
McKesson (MCK) trades at $910.33, down 1.23% over 24 hours, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $9.93 surpassing the $9.56 estimate. Revenue grew to $359.05 billion in 2025, though net margins remain thin at 1.12%. Recent news highlights a key distribution extension with CVS Health through 2032, reinforcing growth visibility in pharmaceutical distribution.
The outlook remains positive given analyst consensus favoring Buy ratings (80.65%) and a price target of $956.43, implying ~5% upside. Risks include margin pressure from drug pricing dynamics and policy uncertainty, while institutional accumulation and solid cash flow generation support stability. Earnings momentum and strategic partnerships position MCK for sustained growth, though investors should monitor competitive and regulatory headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
